| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gustavo Pimentel Dutra, Gustavo L Ottoni, Diogo R Lara, Maurício Reis Bog. Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32. issue 3. 2011-08-16. PMID:20414589. |
adenosine may play a role in the pathophysiology of schizophrenia, since it modulates the release of several neurotransmitters such as glutamate, dopamine, serotonin and acetylcholine, decreases neuronal activity by pos-synaptic hyperpolarization and inhibits dopaminergic activity. |
2011-08-16 |
2023-08-12 |
Not clear |
| Jasper E Visser, David J Schretlen, Bastiaan R Bloem, Hyder A Jinna. Levodopa is not a useful treatment for Lesch-Nyhan disease. Movement disorders : official journal of the Movement Disorder Society. vol 26. issue 4. 2011-08-15. PMID:21506156. |
lnd is associated with a presynaptic dopaminergic deficit, but the reported effects of dopamine replacement therapy are conflicting. |
2011-08-15 |
2023-08-12 |
human |
| David T Dexter, Sarah A Statton, Charlotte Whitmore, Wolfhardt Freinbichler, Peter Weinberger, Keith F Tipton, Laura Della Corte, Roberta J Ward, Robert R Crichto. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 2. 2011-08-12. PMID:21165659. |
focal administration of deferasirox (0.5, 2 and 10 μg) into the substantia nigra pars compacta of rats significantly attenuated the loss of dopaminergic neurons and striatal dopamine content resulting from 6-ohda toxicity. |
2011-08-12 |
2023-08-12 |
rat |
| David T Dexter, Sarah A Statton, Charlotte Whitmore, Wolfhardt Freinbichler, Peter Weinberger, Keith F Tipton, Laura Della Corte, Roberta J Ward, Robert R Crichto. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 2. 2011-08-12. PMID:21165659. |
systemic administration of deferasirox (20 mg/kg), deferiprone (10 mg/kg) or deferrioxamine (30 mg/kg), to the 6-ohda rat model of parkinson's disease, significantly attenuated the loss of dopaminergic neurons and striatal dopamine content. |
2011-08-12 |
2023-08-12 |
rat |
| Yuriko Iwakura, Yingjun Zheng, Maria Sibilia, Yuichi Abe, Ying-Shan Piao, Daisaku Yokomaku, Ran Wang, Yuta Ishizuka, Nobuyuki Takei, Hiroyuki Naw. Qualitative and quantitative re-evaluation of epidermal growth factor-ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1). Journal of neurochemistry. vol 118. issue 1. 2011-08-12. PMID:21517852. |
in mesencephalic culture, egf and glial-derived neurotrophic factor (gdnf) similarly promoted survival and neurite elongation of dopaminergic neurons and dopamine uptake. |
2011-08-12 |
2023-08-12 |
mouse |
| Yuriko Iwakura, Ran Wang, Yuichi Abe, Ying-Shan Piao, Yuji Shishido, Shigeki Higashiyama, Nobuyuki Takei, Hiroyuki Naw. Dopamine-dependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2). Journal of neurochemistry. vol 118. issue 1. 2011-08-12. PMID:21534959. |
therefore, the activation of striatal dopamine receptors induces shedding and release of egf to provide a retrograde neurotrophic signal to midbrain dopaminergic neurons. |
2011-08-12 |
2023-08-12 |
rat |
| Masanari Itokawa, Tadao Arinami, Michio Tor. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. Journal of pharmacological sciences. vol 114. issue 1. 2011-08-11. PMID:20716857. |
hyperactive dopaminergic signal transduction in the central nervous system is suggested to be involved in the pathophysiology of schizophrenia (the dopamine hypothesis). |
2011-08-11 |
2023-08-12 |
Not clear |
| Akinori Nishi, Gretchen L Snyde. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. Journal of pharmacological sciences. vol 114. issue 1. 2011-08-11. PMID:20716858. |
advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. |
2011-08-11 |
2023-08-12 |
Not clear |
| Akinori Nishi, Gretchen L Snyde. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. Journal of pharmacological sciences. vol 114. issue 1. 2011-08-11. PMID:20716858. |
the inhibition of pde up-regulates camp/pka signaling in three neuronal subtypes, resulting in the stimulation of dopamine synthesis at dopaminergic terminals, the inhibition of dopamine d(2)-receptor signaling in striatopallidal neurons, and the stimulation of dopamine d(1)-receptor signaling in striatonigral neurons. |
2011-08-11 |
2023-08-12 |
Not clear |
| Chiho Sumi-Ichinose, Hiroshi Ichinose, Kazuhisa Ikemoto, Takahide Nomura, Kazunao Kond. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: regulation of dopaminergic neural transmission by tyrosine hydroxylase protein at nerve terminals. Journal of pharmacological sciences. vol 114. issue 1. 2011-08-11. PMID:20716859. |
advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: regulation of dopaminergic neural transmission by tyrosine hydroxylase protein at nerve terminals. |
2011-08-11 |
2023-08-12 |
mouse |
| Laurent Coque, Shibani Mukherjee, Jun-Li Cao, Sade Spencer, Marian Marvin, Edgardo Falcon, Michelle M Sidor, Shari G Birnbaum, Ami Graham, Rachael L Neve, Elizabeth Gordon, Angela R Ozburn, Matthew S Goldberg, Ming-Hu Han, Donald C Cooper, Colleen A McClun. Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockΔ19 mouse model of mania. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 7. 2011-08-10. PMID:21430648. |
the increased dopaminergic activity in the clock mutants is associated with cell volume changes in dopamine neurons, which are also rescued by lithium treatment. |
2011-08-10 |
2023-08-12 |
mouse |
| Laurent Coque, Shibani Mukherjee, Jun-Li Cao, Sade Spencer, Marian Marvin, Edgardo Falcon, Michelle M Sidor, Shari G Birnbaum, Ami Graham, Rachael L Neve, Elizabeth Gordon, Angela R Ozburn, Matthew S Goldberg, Ming-Hu Han, Donald C Cooper, Colleen A McClun. Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockΔ19 mouse model of mania. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 7. 2011-08-10. PMID:21430648. |
to determine the role of dopaminergic activity and morphological changes in dopamine neurons in manic-like behavior, we manipulated the excitability of these neurons by overexpressing an inwardly rectifying potassium channel subunit (kir2.1) selectively in the vta of clockΔ19 mice and wild-type mice using viral-mediated gene transfer. |
2011-08-10 |
2023-08-12 |
mouse |
| A Millar, D Smith, J Choueiry, D Fisher, P Albert, V Knot. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience. vol 180. 2011-08-04. PMID:21315807. |
although schizophrenia has been considered primarily a disease of dopaminergic neurotransmission, the role of dopamine in auditory sensory gating deficits in this disorder and their amelioration by smoking/nicotine is unclear. |
2011-08-04 |
2023-08-12 |
Not clear |
| J A L Hutter-Saunders, L M Kosloski, J M McMillan, N Yotam, T Rinat, R L Mosley, H E Gendelma. BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience. vol 180. 2011-08-04. PMID:21320578. |
drug was administered during and after the development of mptp-induced nigrostriatal lesions followed by measures of motor function and behavior, surviving nigrostriatal dopaminergic neurons and termini, and striatal dopamine levels. |
2011-08-04 |
2023-08-12 |
mouse |
| Jens Volkmann, Christine Daniels, Karsten Wit. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nature reviews. Neurology. vol 6. issue 9. 2011-08-03. PMID:20680036. |
the preoperative neuropsychiatric state can be further complicated by sensitization phenomena resulting from long-term dopaminergic treatment, which include impulse control disorders, punding, and addictive behaviors (dopamine dysregulation syndrome). |
2011-08-03 |
2023-08-12 |
Not clear |
| Eric S Ramsson, Daniel P Covey, David P Daberkow, Melissa T Litherland, Steven A Juliano, Paul A Garri. Amphetamine augments action potential-dependent dopaminergic signaling in the striatum in vivo. Journal of neurochemistry. vol 117. issue 6. 2011-08-03. PMID:21443523. |
amphetamine (amph) is thought to disrupt normal patterns of action potential-dependent dopaminergic signaling by depleting dopamine (da) vesicular stores and promoting non-exocytotic da efflux. |
2011-08-03 |
2023-08-12 |
rat |
| Jufang Shan, Jonathan A Javitch, Lei Shi, Harel Weinstei. The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PloS one. vol 6. issue 1. 2011-08-02. PMID:21298009. |
the dopamine transporter (dat), a member of the neurotransmitter:na(+) symporter (nss) family, terminates dopaminergic neurotransmission and is a major molecular target for psychostimulants such as cocaine and amphetamine, and for the treatment of attention deficit disorder and depression. |
2011-08-02 |
2023-08-12 |
Not clear |
| Po See Chen, Tzung Lieh Yeh, I Hui Lee, Cheng Bill Lin, Hsin Chun Tsai, Kao Chin Chen, Nan-Tsing Chiu, Wei Jen Yao, Yen Kuang Yang, Yuan-Hwa Cho. Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers--a SPECT study. NeuroImage. vol 56. issue 3. 2011-07-25. PMID:21371559. |
striatal dopaminergic activity is significantly correlated with various cognitive activities, mood regulation, and even metabolic homeostasis, and is modulated by the dopamine transporter (dat). |
2011-07-25 |
2023-08-12 |
human |
| C Aurich, N Parvizi, D Brunklaus, H O Hoppen, J E Auric. Opioidergic and dopaminergic effects on LH and prolactin release in pony mares at different times of the year. Journal of reproduction and fertility. Supplement. issue 56. 2011-07-20. PMID:20681131. |
no dopaminergic regulation of lh release or interactions between dopamine and opioids was demonstrated. |
2011-07-20 |
2023-08-12 |
Not clear |
| Raul R Gainetdino. Strengths and limitations of genetic models of ADHD. Attention deficit and hyperactivity disorders. vol 2. issue 1. 2011-07-18. PMID:21432587. |
mice lacking the dopamine transporter have elevated dopaminergic tone and represent a genetic animal model in which certain endophenotypes of adhd can be recapitulated. |
2011-07-18 |
2023-08-12 |
mouse |